{
    "2019-03-31": [
        [
            {
                "time": "",
                "original_text": "【上海医药】年报点评：研发投入大幅增长，商业网络继续完善",
                "features": {
                    "keywords": [
                        "上海医药",
                        "年报",
                        "研发投入",
                        "大幅增长",
                        "商业网络",
                        "完善"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "创新疫苗将进入第二波浪潮，重新梳理长期医药十年十倍四大主线【国盛医药张金洋团队】",
                "features": {
                    "keywords": [
                        "创新疫苗",
                        "第二波浪潮",
                        "长期医药",
                        "十年十倍",
                        "四大主线",
                        "国盛医药",
                        "张金洋团队"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}